Published in J Biomed Biotechnol on January 18, 2011
Molecular biology of lung cancer. J Thorac Dis (2013) 1.67
EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer (2012) 1.63
New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol (2012) 1.57
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol (2014) 1.56
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol (2012) 1.23
Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget (2014) 1.08
Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int (2012) 1.05
Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep (2014) 1.00
SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. Oncotarget (2014) 0.97
The Tumor Cytosol miRNAs, Fluid miRNAs, and Exosome miRNAs in Lung Cancer. Front Oncol (2015) 0.96
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther (2014) 0.91
Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem Biophys Res Commun (2012) 0.89
PICT1 expression is a poor prognostic factor in non-small cell lung cancer. Oncoscience (2014) 0.88
Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma. BMC Syst Biol (2013) 0.87
Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest (2015) 0.86
An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling. PLoS One (2015) 0.82
Identification of candidate genes for lung cancer somatic mutation test kits. Genet Mol Biol (2013) 0.82
Utilisation of nanoparticle technology in cancer chemoresistance. J Drug Deliv (2012) 0.81
Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly. PLoS One (2015) 0.80
Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib. Oncotarget (2015) 0.80
Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. J Thorac Dis (2015) 0.80
A novel differential diagnostic model for multiple primary lung cancer: Differentially-expressed gene analysis of multiple primary lung cancer and intrapulmonary metastasis. Oncol Lett (2015) 0.78
Genotyping of Human Papillomavirus and TP53 Mutaions at Exons 5 to 7 in Lung Cancer Patients from Iran. Bioimpacts (2013) 0.78
The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging (2016) 0.78
TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment. Sci Rep (2015) 0.78
A negative regulation loop of long noncoding RNA HOTAIR and p53 in non-small-cell lung cancer. Onco Targets Ther (2016) 0.77
Correlation of neuroendocrine features with prognosis of non-small cell lung cancer. Oncotarget (2016) 0.77
Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism. Cancer Biother Radiopharm (2012) 0.77
Role of Exosomal Noncoding RNAs in Lung Carcinogenesis. Biomed Res Int (2015) 0.77
Overexpression of G protein-coupled receptor 87 correlates with poorer tumor differentiation and higher tumor proliferation in non-small-cell lung cancer. Mol Clin Oncol (2014) 0.77
Nanomaterial-Enabled Cancer Therapy. Mol Ther (2017) 0.77
Involvement of p53 mutation and mismatch repair proteins dysregulation in NNK-induced malignant transformation of human bronchial epithelial cells. Biomed Res Int (2014) 0.76
Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer. Lung Cancer (Auckl) (2011) 0.75
Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. Int J Mol Sci (2017) 0.75
Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci (2017) 0.75
Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance. Genes (Basel) (2017) 0.75
Prognostic factors in resected lung carcinomas. EJC Suppl (2013) 0.75
Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition. Biomark Cancer (2016) 0.75
Leveraging protein quaternary structure to identify oncogenic driver mutations. BMC Bioinformatics (2016) 0.75
Modification of tumor cell exosome content by transfection with wt-p53 and microRNA-125b expressing plasmid DNA and its effect on macrophage polarization. Oncogenesis (2016) 0.75
Population effect model identifies gene expression predictors of survival outcomes in lung adenocarcinoma for both Caucasian and Asian patients. PLoS One (2017) 0.75
Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing. Cancer Inform (2015) 0.75
Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. Oncotarget (2016) 0.75
Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology. Oncotarget (2016) 0.75
Effect of the p53α gene on the chemosensitivity of the H1299 human lung adenocarcinoma cell line. Oncol Lett (2017) 0.75
Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. Oncogene (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Surfing the p53 network. Nature (2000) 35.36
p53 mutations in human cancers. Science (1991) 31.96
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 14.05
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
MORTALITY IN RELATION TO SMOKING: TEN YEARS' OBSERVATIONS OF BRITISH DOCTORS. Br Med J (1964) 12.84
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 11.05
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature (1991) 7.49
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 5.18
Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science (1996) 5.17
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
p53 and human cancer: the first ten thousand mutations. Adv Cancer Res (2000) 4.71
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene (2007) 4.27
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov (2008) 4.03
Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol (1979) 3.81
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res (2000) 3.30
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J (2001) 3.04
Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene (1990) 2.97
Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst (1999) 2.83
Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis (2001) 2.66
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51
The p53 functional circuit. J Cell Sci (2001) 2.46
Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. Virology (1979) 2.38
Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell (2007) 2.31
Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol (2007) 2.30
Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst (2000) 2.27
Mutational spectra of human cancer. Hum Genet (2009) 2.26
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res (1997) 2.17
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer (2006) 2.05
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.03
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol (2008) 1.87
The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat (2003) 1.86
Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst (1994) 1.83
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle (2010) 1.75
Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol (2010) 1.64
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene (1992) 1.63
Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene (2007) 1.62
Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res (1992) 1.60
Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res (1994) 1.59
Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res (2000) 1.55
The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene (1991) 1.51
p53: 25 years after its discovery. Trends Pharmacol Sci (2004) 1.49
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst (1999) 1.47
p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. Carcinogenesis (1996) 1.46
Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther (2010) 1.41
High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene (1992) 1.41
Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res (1995) 1.34
p53 mutations in human lung tumors. Cancer Res (1992) 1.33
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res (1995) 1.29
Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol (2008) 1.28
Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev (1999) 1.25
Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ (2006) 1.23
p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res (2001) 1.23
The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun (2005) 1.16
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol (2000) 1.16
Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol (2003) 1.15
PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene (2005) 1.13
Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene (1992) 1.10
30 years and a long way into p53 research. Lancet Oncol (2009) 1.10
Mutant p53 gain of function: the NF-Y connection. Cancer Cell (2006) 1.08
Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol (1990) 1.08
p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann N Y Acad Sci (2000) 1.05
Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle (2007) 1.03
A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol (1996) 1.02
p53 mutations in primary human lung tumors and their metastases. Mol Carcinog (1994) 1.02
Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev (1999) 1.01
Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol (2010) 0.99
Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol (2009) 0.94
The p53 pathway and human cancer. Br J Surg (2005) 0.93
Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest (2000) 0.93
p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res (2000) 0.92
Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer. Oncogene (1991) 0.92
A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ Health Perspect (1998) 0.91
Lung cancer mortality patterns in selected Central, Eastern and Southern European countries. Int J Cancer (2004) 0.91
The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene (1998) 0.91
p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br J Cancer (1998) 0.87
Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J Thorac Cardiovasc Surg (2008) 0.85
PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. J Cell Biochem (2008) 0.85
TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. Mutagenesis (2001) 0.85
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol (2010) 0.84
Radiotherapy of lung cancer: technology meets biology meets multidisciplinarity. Radiother Oncol (2009) 0.83
Molecular epidemiology of human cancer. Recent Results Cancer Res (1998) 0.82
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res (2006) 4.62
The diagnosis and treatment of adult intussusception. J Clin Gastroenterol (2003) 3.06
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol (2010) 2.73
Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells. Ann Surg Oncol (2008) 2.56
Laparoscopic assisted distal gastrectomy for early gastric cancer: Five years' experience. Surgery (2005) 2.06
Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer (2010) 1.93
Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol (2004) 1.89
IL-15 regulates CD8+ T cell contraction during primary infection. J Immunol (2006) 1.88
Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg (2004) 1.87
Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol (2009) 1.85
Thoracic and cardiovascular surgery in Japan during 2011: Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg (2013) 1.84
Laparoscopically assisted total gastrectomy with lymph node dissection for upper and middle gastric cancer. Surg Endosc (2008) 1.82
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol (2009) 1.81
Gum chewing enhances early recovery from postoperative ileus after laparoscopic colectomy. J Am Coll Surg (2002) 1.77
c-myc is a downstream target of the Smad pathway. J Biol Chem (2001) 1.74
EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer (2003) 1.68
Thoracic and cardiovascular surgery in Japan during 2012 : annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg (2014) 1.65
Laparoscopy-assisted proximal gastrectomy with gastric tube reconstruction for early gastric cancer. Surg Endosc (2010) 1.65
The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer (2005) 1.64
Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol (2007) 1.62
Should patients over 85 years old be operated on for colorectal cancer? J Clin Gastroenterol (2004) 1.52
Overexpression of IL-15 in vivo increases antigen-driven memory CD8+ T cells following a microbe exposure. J Immunol (2002) 1.51
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol (2006) 1.50
Adenovirus-mediated overexpression of the activin betaC subunit accelerates liver regeneration in partially hepatectomized rats. J Hepatol (2005) 1.45
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol (2011) 1.42
Impact of gastropyloric motor activity on the genesis of reflux esophagitis after an esophagectomy with gastric tube reconstruction. Ann Thorac Surg (2013) 1.42
Gastrointestinal recovery and outcome after laparoscopy-assisted versus conventional open distal gastrectomy for early gastric cancer. World J Surg (2002) 1.41
Is an elderly recipient a risk for living donor adult liver transplantation? Hepatogastroenterology (2008) 1.38
p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res (2009) 1.37
Thoracic and cardiovascular surgery in Japan during 2009: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg (2011) 1.35
MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol (2011) 1.34
Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer (2003) 1.31
High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res (2002) 1.30
Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res (2013) 1.29
Thoracoscopic treatment of Bochdalek hernia in the adult: report of a case. Ann Thorac Cardiovasc Surg (2002) 1.29
Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer (2002) 1.28
MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci (2012) 1.27
Distal pancreatectomy: is staple closure beneficial? ANZ J Surg (2003) 1.25
Laparoscopic appendectomy for appendiceal endometriosis presenting as acute appendicitis: report of a case. Surg Today (2007) 1.25
Selenium enrichment of broccoli sprout extract increases chemosensitivity and apoptosis of LNCaP prostate cancer cells. BMC Cancer (2009) 1.25
Thoracic and cardiovascular surgery in Japan during 2008: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg (2010) 1.24
Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer (2011) 1.23
18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg (2005) 1.22
Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin. Int J Cancer (2011) 1.21
Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT. Jpn J Clin Oncol (2008) 1.18
Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer (2003) 1.17
Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep (2004) 1.16
Schwannoma of the breast: report of a case. Surg Today (2005) 1.16
Safe and effective sedation in endoscopic submucosal dissection for early gastric cancer: a randomized comparison between propofol continuous infusion and intermittent midazolam injection. J Gastroenterol (2010) 1.15
Implication of galectin-3 in Wnt signaling. Cancer Res (2005) 1.12
Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol (2007) 1.11
Primary squamous cell carcinoma of the stomach: a case report with immunohistochemical and molecular biologic studies. Hepatogastroenterology (2005) 1.10
Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res (2005) 1.10
Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol Rep (2006) 1.09
Hepatocellular carcinoma producing a granulocyte colony-stimulating factor: report of a resected case with a literature review. Liver Int (2007) 1.07
Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog (2008) 1.07
Thoracic and cardiovascular surgery in Japan during 2007. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg (2009) 1.07
The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer (2009) 1.07
CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol (2008) 1.06
Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res (2004) 1.06
Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas. Anticancer Res (2005) 1.06
Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res (2008) 1.05
Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer (2007) 1.05
Esophageal granular cell tumor covered by intramucosal squamous cell carcinoma: report of a case. Surg Today (2008) 1.05
Gastric schwannomas show an obviously increased fluorodeoxyglucose uptake in positron emission tomography: report of two cases. Surg Today (2011) 1.05
Nuclear karyopherin-α2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer. Carcinogenesis (2013) 1.05
Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene (2003) 1.05
Increased expression of c-Ski as a co-repressor in transforming growth factor-beta signaling correlates with progression of esophageal squamous cell carcinoma. Int J Cancer (2004) 1.04
Significance of karyopherin-{alpha} 2 (KPNA2) expression in esophageal squamous cell carcinoma. Anticancer Res (2010) 1.04
Predictive value of blood flow in the gastric tube in anastomotic insufficiency after thoracic esophagectomy. World J Surg (2002) 1.04
Clinical and prognostic significance of RhoA and RhoC gene expression in esophageal squamous cell carcinoma. Ann Surg Oncol (2007) 1.03
alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer (2004) 1.03
Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer (2009) 1.02
Laparoscopy-assisted gastrectomy for early gastric cancer in young and elderly patients. World J Surg (2005) 1.02
Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Cancer Sci (2014) 1.01
Thickness of subcutaneous fat as a strong risk factor for wound infections in elective colorectal surgery: impact of prediction using preoperative CT. Dig Surg (2010) 1.01
The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polyp formation in Apc(Min/+) mice. Carcinogenesis (2003) 0.99
Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int J Oncol (2006) 0.99
Enforced expression of Bcl-2 partially restores cell numbers but not functions of TCRgammadelta intestinal intraepithelial T lymphocytes in IL-15-deficient mice. J Immunol (2007) 0.99
Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway. Arterioscler Thromb Vasc Biol (2006) 0.99
Comparing endoscopic submucosal dissection with transanal resection for non-invasive rectal tumor: a retrospective study. J Gastroenterol Hepatol (2011) 0.99
Esophageal granular cell tumor successfully resected by endoscopic submucosal dissection. Esophagus (2011) 0.99
Gum-chewing stimulates bowel motility after surgery for colorectal cancer. Hepatogastroenterology (2006) 0.99
Significant correlation between expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous cell carcinoma. Cancer Lett (2002) 0.98
Implication of extracapsular invasion of sentinel lymph nodes in breast cancer: prediction of nonsentinel lymph node metastasis. World J Surg (2010) 0.98
Laparoscopic transgastric tumor-everting resection of the gastric submucosal tumor located near the esophagogastric junction. Surg Laparosc Endosc Percutan Tech (2004) 0.98
A novel role of IL-15 in early activation of memory CD8+ CTL after reinfection. J Immunol (2005) 0.98
LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci (2007) 0.98
Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer (2002) 0.97
Effect of intraportal infusion to improve small for size graft injury in living donor adult liver transplantation. Transpl Int (2005) 0.97
Torsion of the gallbladder diagnosed by magnetic resonance cholangiopancreatography. Int Surg (2012) 0.96
Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol (2010) 0.96
Sudden bilateral sensorineural hearing loss as the presenting symptom of meningeal carcinomatosis of gastric cancer: report of a case. Surg Today (2010) 0.96
Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness. Ann Surg Oncol (2010) 0.96
Sentinel lymph nodes with technetium-99m colloidal rhenium sulfide in patients with esophageal carcinoma. Cancer (2003) 0.95
Correlation between laminin-5 gamma2 chain and epidermal growth factor receptor expression in esophageal squamous cell carcinomas. Oncology (2005) 0.95
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res (2003) 0.95
Thoracoscopic resection of a mesenchymal cystic hamartoma of the lung. Gen Thorac Cardiovasc Surg (2011) 0.94
Complete appendiceal intussusception induced by primary appendiceal adenocarcinoma in tubular adenoma: a case report. Jpn J Clin Oncol (2003) 0.94